Purpose: To determine whether tumor perfusion parameters assessed by using dynamic contrast material–enhanced computed tomography (CT) could help predict and detect response in patients receiving antiangiogenic therapy for metastatic renal cell carcinoma. Materials and Methods: Institutional ethics committee approval and informed consent were obtained. In two phase-III trials involving 51 patients with metastatic renal cell carcinoma (38 men, 13

To determine the benefit of starting early chemotherapy with docetaxel (the recommended first-line treatment) for patients with asymptomatic metastatic hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS Data were analysed from 145 patients with HRPC treated with chemotherapy between February 2000 and June 2002 in one French centre. Eligible patients were categorized into three groups according to the bone pain at baseline, i.e. minimal/no

The successful management of prostate cancer requires early detection, appropriate risk assessment and optimum treatment. To this end, much research has been conducted over many years with the goal of identifying a reliable and easily measurable tumour marker that could be used on a large scale for the diagnosis, staging and monitoring of the disease. Prostate-specific antigen (PSA) was independently discovered by two groups in the 1960s and 1970s,

Abstract We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10mg/kg) in combination with sunitinib 25–50mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1

OBJECTIVE: To review the current practices for metastatic non–small cell lung cancer (NSCLC) management and highlight the latest progress. DATA SOURCES: A literature review using HighWire Press (1960–May 2008) was conducted using the following key words: non–small cell lung cancer, chemotherapy, supportive care, therapeutic strategy, quality of life (QOL), and targeted therapies. STUDY SELECTION AND DATA EXTRACTION: Review articles, clinical

BACKGROUND: Among multiple lung cancers (MLC), some may have similar histologic classification. Demonstrating that the second tumor is a metastasis would change the stage and consequently the management. Our purpose was to reconsider this consequence. METHODS: We reviewed 234 patients (194 male and 40 female, from 37 to 83 years of age) with synchronous and metachronous non-small cell MLC. Surgery consisted of a potentially curative complete resection

To the Editor: When we first reviewed factors determining overall survival of resected N2 nonsmall lung cancers (NSCLC) [1], we observed that the presence of a small metastasis in a mediastinal lymph node had the same clinical significance as that of a whole chain of tumor-bearing lymph nodes with extracapsular invasion. In recent years, minimal N2 disease is emerging as a criterion of better prognosis for NSCLC patients with mediastinal lymph node

Background: Several studies suggest a causal relationship between platelet activation and cancer metastasis. Activated platelet microparticles (PMPs) release vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which play a major role in angiogenesis. Objective: We conducted a prospective, nonrandomised, single-centre study in hormone-refractory prostate cancer (HRPC) patients to determine the impact of PMPs on the

This phase II study was initiated to detennine the efficacy and tolerability of gemcitabine added to «De Gramonb> regimen as first line chemotherapy (CT) for advanced/metastatic pancreatic carcinoma. From 1/1999 to 4/2000,23 chemonalve patients were enrolled. Up to 6 cycles ofFOLFUGEM regimen were given: Folinic acid 200 mg/m2 in 2 ills, 5-FU 400 mg/m2 in bolus, 5-FU 600 mg/m2 in 22 hrs infusion days 1,2 and Gemcitabine 800 mg/m2 in 1 hr on d2,

Vinorelbine is considered the most active Vinka alkaloid in NSCLC, and its association with Cisplatin is still considered the most cost/effective protocol in many institutions. Purpose: To assess, in a phase II trial, the results obtained in locoregionally advanced (stage III B) NSCLC patients with VP combination, delivered in an outpatient setting. Methods: From VIU1999 to V /2000,23 previously untreated patients received VP (Vinorelbine 25 mg/m2,